Bone Biologics Corp cash flow statement

In fiscal 2020, Bone Biologics Corp's operations generated −$426,933 of cash; it spent $0 on capital projects, leaving free cash flow of −$426,933.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Bone Biologics Corp: cash flow statement, annual
Fiscal year	2016Dec 2016	2019Dec 2019	2020Dec 2020	LTMJun 2021
Cash from operations	−7	−3	−0	−1
Depreciation and amortisation	0	0	—	—
Stock-based pay	4	0	—	—
Capital spending	0	0	0	0
Free cash flow	−7	−3	−0	−1
Free cash flow after stock pay	−11	−3	—	—
Shares issued	3	—	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Bone Biologics Corp: cash flow statement, quarterly
Quarter	2018 Q4Dec 2018	2019 Q1Mar 2019	2020 Q1Mar 2020	2020 Q2Jun 2020	2020 Q3Sept 2020	2020 Q4Dec 2020	2021 Q1Mar 2021	2021 Q2Jun 2021
Cash from operations	−1,339	−929	−150	−79	−72	−126	−128	−636
Depreciation and amortisation	0	0	—	—	—	—	—	—
Stock-based pay	24	26	—	—	—	—	—	—
Capital spending	0	0	0	0	0	0	0	0
Free cash flow	−1,339	−929	−150	−79	−72	−126	−128	−636
Free cash flow after stock pay	−1,363	−955	—	—	—	—	—	—
Shares issued	0	—	—	—	—	—	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Bone Biologics Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bone Biologics Corp.